CN104870013A - 用于抑制炎症的抗-cxcl9、抗-cxcl10、抗-cxcl11、抗-cxcl13、抗-cxcr3和抗-cxcr5试剂 - Google Patents

用于抑制炎症的抗-cxcl9、抗-cxcl10、抗-cxcl11、抗-cxcl13、抗-cxcr3和抗-cxcr5试剂 Download PDF

Info

Publication number
CN104870013A
CN104870013A CN 201280075412 CN201280075412A CN104870013A CN 104870013 A CN104870013 A CN 104870013A CN 201280075412 CN201280075412 CN 201280075412 CN 201280075412 A CN201280075412 A CN 201280075412A CN 104870013 A CN104870013 A CN 104870013A
Authority
CN
Grant status
Application
Patent type
Prior art keywords
anti
antibody
inflammatory
cxcl9
cxcr3
Prior art date
Application number
CN 201280075412
Other languages
English (en)
Chinese (zh)
Inventor
詹姆斯·W·利拉德
Original Assignee
吉安特科技公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
CN 201280075412 2012-06-27 2012-06-27 用于抑制炎症的抗-cxcl9、抗-cxcl10、抗-cxcl11、抗-cxcl13、抗-cxcr3和抗-cxcr5试剂 CN104870013A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/US2012/044464 WO2014003742A1 (en) 2012-06-27 2012-06-27 Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation

Publications (1)

Publication Number Publication Date
CN104870013A true true CN104870013A (zh) 2015-08-26

Family

ID=49783685

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 201280075412 CN104870013A (zh) 2012-06-27 2012-06-27 用于抑制炎症的抗-cxcl9、抗-cxcl10、抗-cxcl11、抗-cxcl13、抗-cxcr3和抗-cxcr5试剂

Country Status (4)

Country Link
EP (1) EP2866830A4 (ja)
JP (1) JP2015524793A (ja)
CN (1) CN104870013A (ja)
WO (1) WO2014003742A1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106459971A (zh) * 2014-04-08 2017-02-22 弗劳恩霍夫应用研究促进协会 用于治疗自身免疫性疾病的联合疗法
CN105039319A (zh) * 2015-06-22 2015-11-11 浙江理工大学 用于预测乳腺癌新辅助化疗疗效的生物标记物和荧光定量免疫pcr试剂盒

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004045525A2 (en) * 2002-11-15 2004-06-03 Morehouse School Of Medicine Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation.
CN101842115A (zh) * 2007-08-29 2010-09-22 塞诺菲-安万特股份有限公司 人源化的抗-cxcr5抗体、其衍生物及它们的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014505239A (ja) * 2010-12-14 2014-02-27 モアハウス スクール オブ メディスンMorehouse School Of Medicine 癌の治療または検出のための抗cxcl13および抗cxcr5抗体の使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004045525A2 (en) * 2002-11-15 2004-06-03 Morehouse School Of Medicine Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation.
CN101842115A (zh) * 2007-08-29 2010-09-22 塞诺菲-安万特股份有限公司 人源化的抗-cxcr5抗体、其衍生物及它们的应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A. BUSUTTIL: "CXCR3 ligands are augmented during the", 《EUROPEAN RESPIRATORY JOURNAL》 *
SEBASTIAN SCHROEPF ET AL.: "Strong Overexpression of CXCR3 Axis Components in Childhood Inflammatory Bowel Disease", 《INFLAMM BOWEL DIS》 *

Also Published As

Publication number Publication date Type
EP2866830A1 (en) 2015-05-06 application
EP2866830A4 (en) 2015-12-09 application
WO2014003742A1 (en) 2014-01-03 application
JP2015524793A (ja) 2015-08-27 application

Similar Documents

Publication Publication Date Title
Serafini et al. Intracerebral recruitment and maturation of dendritic cells in the onset and progression of experimental autoimmune encephalomyelitis
Dominguez-Sola et al. The proto-oncogene MYC is required for selection in the germinal center and cyclic reentry
Nacionales et al. Deficiency of the type I interferon receptor protects mice from experimental lupus
US20060039910A1 (en) Methods and compositions for treating allergic inflammation
US20050014224A1 (en) GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
Kasperkiewicz et al. Pemphigoid diseases: pathogenesis, diagnosis, and treatment
US20040156849A1 (en) Inhibition of IL-17 production
Damsker et al. Targeting the chemotactic function of CD147 reduces collagen‐induced arthritis
US20080199460A1 (en) Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
Holtmann et al. Tumor necrosis factor‐receptor 2 is up‐regulated on lamina propria T cells in Crohn's disease and promotes experimental colitis in vivo
WO2005026209A2 (en) Monoclonal antibodies against hmgb1
Wang et al. Effects of anti‐CD154 treatment on B cells in murine systemic lupus erythematosus
US20040191255A1 (en) Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation
US8187596B1 (en) Method of treating asthma or allergy by administering an IL-33 receptor antibody
Czura et al. HMGB1 in the immunology of sepsis (not septic shock) and arthritis
US20030017155A1 (en) Antagonists of HMG1 for treating inflammatory conditions
WO2004060295A2 (en) Methods of inducing and maintaining immune tolerance
WO2006088925A2 (en) Use of il17-f in diagnosis and therapy of airway inflammation
Joosten et al. T cell dependence of chronic destructive murine arthritis induced by repeated local activation of toll‐like receptor–driven pathways: Crucial role of both interleukin‐1β and interleukin‐17
Qing et al. Pathogenic anti-DNA antibodies modulate gene expression in mesangial cells: involvement of HMGB1 in anti-DNA antibody-induced renal injury
WO2006068987A2 (en) Uses of il-23 antagonists in the treatment of diabetes mellitus
WO2006088833A2 (en) Interleukin-17f antibodies and other il-17f signaling antagonists and uses therefor
US20080075728A1 (en) Combination Therapies Of Hmgb And Complement Inhibitors Against Inflammation
WO2004050706A2 (en) Regulatory t-cells
US20070172856A1 (en) Materials and methods for treating chronic fibrotic diseases

Legal Events

Date Code Title Description
EXSB Decision made by sipo to initiate substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1212628

Country of ref document: HK